|
消块止痛丹联合西药治疗痛风性关节炎气虚湿阻型的临床观察
|
Abstract:
目的:观察消块止痛丹联合西药治疗慢性痛风性关节炎气虚湿阻型的临床疗效及对肿瘤坏死因子-α (tumor necrosis factor alpha, TNF-α)、白细胞介素-6 (interleukin-6, IL-6)、白细胞介素-8 (interleukin-8, IL-8)和超敏C反应蛋白(hypersensitive C-reactive protein, hs-CRP)水平的影响。方法:对照组60例接受非布司他片,40 mg/次,1次/d,饭后服用,美洛昔康分散片7.2 mg/次,2次/d,口服。观察组60例患者在对照组的基础上接受消块止痛丹中草药治疗。治疗12周后,观察治疗前后中医症状评分、症状体征、手足关节X线评分。检测治疗前后血尿酸、TNF-α、IL-6、IL-8、hs-CRP水平。结果:治疗后观察组患者肿胀度评分、关节疼痛VAS评分、痛风石数量评分、触诊压痛评分、皮肤红晕评分、关节畸形评分、手足关节X线评分、中医症状评分、血清尿酸、TNF-α、IIL-6、IL-8、hs-CRP水平均低于对照组。结论:消块止痛丹联合西药治疗痛风性关节炎患者能明显改善临床症状及体征,减轻手足关节X线表现,降低血清尿酸及炎症因子水平。
Objective: To observe the clinical efficacy of Xiaokuai Zhitong Dan combined with Western medicine in the treatment of chronic gouty arthritis with qi deficiency and dampness obstruction, and its effects on the levels of tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8), and hypersensitive C-reactive protein (hs-CRP). Method: A control group of 60 patients received febuxostat tablets, 40 mg/time, once a day, taken after meals, and Meloxicam dispersible tablets, 7.2 mg/time, twice a day, orally. 60 patients in the observation group received herbal treatment with Xiaokuan Zhitong Dan on the basis of the control group. After 12 weeks of treatment, the TCM symptom scores, symptom signs, and hand-foot joint X-ray scores before and after treatment were observed. The levels of blood uric acid, TNF-α, IL-6, IL-8, and hs-CRP before and after treatment were measured. Result: After treatment, the swelling score, joint pain VAS score, gouty stone count score, palpation tenderness score, skin redness score, joint deformity score, hand-foot joint X-ray score, traditional Chinese medicine symptom score, serum uric acid, TNF-α, IIL-6, IL-8, and hs-CRP levels in the observation group were lower than those in the control group on average. Conclusion: The combination of Xiaokuai Zhitong Dan combined with Western medicine can significantly improve clinical symptoms and signs, alleviate X-ray manifestations of hand and foot joints, and reduce serum uric acid and inflammatory factor levels in patients with gouty arthritis.
[1] | 潘媛, 徐立, 时乐, 等. 痛风性关节炎的发生与尿酸盐结晶沉积[J]. 安徽医药, 2009, 13(11): 1305-1307. |
[2] | 郭赫, 倪青. 高尿酸血症与痛风的诊断与中医药治疗策略[J]. 中国临床医生杂志, 2018, 46(11): 1268-1270. |
[3] | 卢舒浩, 赵婷, 张喜召, 等. 范永升应用四妙散治疗痛风性关节炎经验举隅[J]. 浙江中医药大学学报, 2017, 41(10): 806-809. |
[4] | 杨雪, 薛愉, 邹和建, 等. 慢性痛风的治疗[J]. 上海医药, 2015, 36(11): 7-11. |
[5] | 黄文莉, 那蕊, 高菲, 等. 痛风石切除术后患者快速康复影响因素的探讨[J]. 临床医药文献杂志, 2017, 4(23): 4418-4419. |
[6] | 沙湖, 梁翼, 余文景, 等. 双合汤加减联合非布司他治疗慢性痛风石性关节炎临床观察[J]. 四川中医, 2019, 37(5): 129-132. |
[7] | 杜静. 中医药治疗痛风临床研究概况[J]. 山东中医药大学学报, 2014, 38(2): 174-177. |
[8] | 金彩云, 谢红艳, 谢春光. 痛风中医病机的探讨[J]. 光明中医, 2018, 33(1): 44-46. |
[9] | 中华医学会风湿病学分会. 2016中国痛风诊疗指南[J]. 浙江医学, 2017, 39(21): 1823-1832. |
[10] | 国家中医药管理局.中医病证诊断疗效标准[M]. 南京: 南京大学出版社, 1994: 50. |
[11] | 郑筱萸. 中药新药临床研究指导原则(试行) [M]. 北京: 中国医药科技出版社, 2002: 115-119. |
[12] | 李丹, 张剑勇. 痛风现代流行病学及降尿酸药物研究进展[J]. 风湿病与关节炎, 2016, 5(4): 73-76. |
[13] | 赖爱云, 徐健, 陶丽. 非布司他片联合依托考昔治疗痛风性关节炎的效果及对血清炎症因子的影响[J]. 中国医药导报, 2018, 15(9): 101-104. |
[14] | 程俊敏, 陈丽川, 熊源胤. 张荒生教授治疗痛风性关节炎经验[J]. 时珍国医国药, 2017, 28(6): 1471-1472. |
[15] | 倪青, 孟祥. 高尿酸血症和痛风中医认识与治疗[J]. 北京中医药, 2016, 36(6): 529-535. |
[16] | 李满意, 娄玉钤. 痛风的源流及历史文献复习[J]. 风湿病与关节炎, 2018, 7(6): 57-62. |
[17] | 肖楠, 董雨潇, 刘佳伟, 等. 利用文献研究中医治疗痛风性关节炎的用药特点[J]. 沈阳药科大学学报, 2019, 36(5): 427-432. |